PCM
NEOS

Prelude Capital Management’s Neos Therapeutics, Inc NEOS Stock Holding History

Prelude Capital Management’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-38,908
Closed -$189K – 2313
2018
Q3 		$189K Hold
38,908
– – 0.01% 780
2018
Q2 		$243K Sell
38,908
-9,624
-20% -$71.7K 0.02% 711
2018
Q1 		$403K Buy
48,532
+2,811
+6% +$26.8K 0.03% 495
2017
Q4 		$466K Sell
45,721
-46,846
-51% -$450K 0.04% 444
2017
Q3 		$847K Buy
92,567
+28,410
+44% +$216K 0.08% 273
2017
Q2 		$468K Buy
64,157
+33,000
+106% +$249K 0.04% 342
2017
Q1 		$224K Buy
31,157
+16,570
+114% +$103K 0.02% 529
2016
Q4 		$85K Buy
+14,587
New +$98.7K 0.01% 883

Other funds holding NEOS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's NEOS Position: Q4 2018 in Review

Prelude Capital Management sold out of Neos Therapeutics, Inc (NEOS) in Q4 2018, closing a stake of 38,908 shares — an estimated $189K sold.

Prelude Capital Management first reported a position in NEOS in Q4 2016 and held it in 8 quarters. The position peaked at $847K in Q3 2017. 63 funds tracked by Wall St. Rank hold NEOS as of Q4 2018.

  • Prelude Capital Management reported no remaining Neos Therapeutics, Inc position as of Q4 2018 after selling out during the quarter.
  • Prelude Capital Management sold 38,908 Neos Therapeutics, Inc shares in Q4 2018, an estimated $189K.
  • Prelude Capital Management first reported a position in Neos Therapeutics, Inc in Q4 2016 and held it in 8 quarters.
  • Prelude Capital Management's Neos Therapeutics, Inc position peaked at $847K in Q3 2017.
  • 63 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.